Infrared light therapy hat for adults with drug-resistant epilepsy
Official title: An Open Label Pilot Study of Infrared Photobiomodulation in Humans With Epilepsy
Run by Beth Israel Deaconess Medical Center · NCT07145489 · Data updated 2026-11-12
This will try an infrared red-light therapy hat in adults with drug-resistant epilepsy to see if it reduces seizures and is comfortable to wear.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 13 (estimated) |
| Sponsor | Beth Israel Deaconess Medical Center Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | November 25, 2025 |
| Main results expected | September 25, 2026 |
| Study ends | September 25, 2027 |
| Registry record updated | February 4, 2026 |
| Trial ID | NCT07145489 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with drug-resistant epilepsy who have an average of at least two seizures per month and maintain an accurate seizure diary are the intended candidates, provided they do not have excluded conditions like implanted intracranial devices or photosensitivity.
✕Probably not a fit
Patients with implanted intracranial neurostimulation devices, intracranial shunts, scalp cancer, known photosensitivity, or taking photosensitizing medications are excluded and are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This first-in-human trial gives all participants an investigational Red Light Therapy Hat to test safety, tolerability, and effects on seizure frequency. The device has shown seizure-reducing effects in animal models but has not been tested for epilepsy in people. Participants must be adults with drug-resistant epilepsy who keep an accurate seizure diary and have at least two seizures per month; key exclusions include intracranial stimulators, shunts, scalp cancer, or photosensitivity. Study visits take place at Beth Israel Deaconess Medical Center and will monitor seizure counts and device tolerability over the treatment period.
Why it matters
Potential benefit: If successful, the device could reduce seizure frequency and offer a noninvasive treatment option for adults whose seizures do not respond to medications.
How similar studies have gone: Preclinical animal studies have suggested seizure reduction with infrared photobiomodulation, but its use for human epilepsy is novel and unproven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Drug resistant epilepsy * Age 18 or older * Average seizure rate of at least 2 seizures per month * Accurate seizure diary with at least 3 months recorded Exclusion Criteria: * Implanted intracranial neurostimulation device (DBS or RNS) * Intracranial shunt * Skin photosensitivity * Cancer on scalp * Taking any medication that can cause photosensitivity
Where it's running
-
Bidmc
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Daniel Goldenholz, MD PhD — Beth Israel Deaconess Medical Center
- Study coordinator: Daniel Goldenholz, MD, PhD
- Email: daniel.goldenholz@bidmc.harvard.edu
- Phone: 617-632-8930
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Modified ketogenic diet for adults with drug-resistant epilepsy
This study tests whether a modified ketogenic diet can help adults with drug-resistant epilepsy see fewer seizures and feel better overall.
-
Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy
This study tests whether low intensity focused ultrasound can help reduce seizures in adults with drug‑resistant epilepsy.
-
iVEAcare Neuromodulation System for drug‑resistant epilepsy: a feasibility look
This study tests whether the iVEAcare neuromodulation system is safe and can help reduce seizures and improve quality of life in people with drug‑resistant epilepsy.
-
Real-world use of the OneRF Ablation System for epilepsy
This registry collects real-world outcomes and device performance from patients with drug-resistant epilepsy who are treated with SEEG-guided RF ablation using the OneRF system.
-
Overnight Temporal Interference Stimulation for Temporal Lobe Epilepsy
This study tests whether overnight, non-invasive temporal interference stimulation to the hippocampus can reduce seizure-related brain activity and improve sleep in adults with drug-resistant temporal lobe epilepsy.
-
Biomarkers of Response to SEEG Thermocoagulation
This study tests biomarkers to see if they predict how well SEEG-guided radiofrequency thermocoagulation helps people with drug-resistant focal epilepsy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.